Advice Pool
#1 in Business Subscribe Email Print

You are here: Home > Health and Fitness > Alternative > How Does Detoxamin EDTA Chelation Compare with Intravenous Treatment?

Tags

  • categories
  • paint
  • companies
  • during world

  • Links

  • Google PageRank Explained
  • How To Build A Web Site & Develop It's Full Potential - Part One
  • Real Estate and Your Retirement
  • Advice Pool - How Does Detoxamin EDTA Chelation Compare with Intravenous Treatment?

    Detoxamin EDTA Chelation Therapy Suppositories are a new form of a treatment that dates back more than 80 years. Chelati
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    on (pronounced key-LAY-shun) is a way to remove heavy metals from the body through the use of chelating agents. The first chelating agent
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    s for medicinal use were developed as an antidote for the arsenic based poison gas used during World War One. During World War Two, when
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    a high number of sailors were exposed to lead paint, used on navy ships, another form of chelation was developed to treat lead poisoning.
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    This was EDTA chelation. EDTA stands for the chemical compound Ethylene-Diamine-Tetra-Acetic acid.

    The way Detoxamin EDTA and other che
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    lating agents work is that they form chemical bonds with the toxic metals, so that the bonded agents and metals can be excreted from the
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    body in the urine. Of course, very few people today come into contact with military poison gas or lead navy paint. But nevertheless, unwa
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    nted heavy metals in the body are a bigger problem in the 21st century than ever before. In fact, people today are living in an environme
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    nt much more toxic than the human body was designed to cope with. A 2003 article in the Miami Herald newspaper (Being Careful Can't Keep
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    Chemicals Out of Your Body) stated that chemical contamination is becoming an almost universal problem, with everyone in contemporary soc
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    ety having toxic chemicals building up in their bodies. Although some people suffer worse than others, nobody is completely free from the
    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    problem.

    Detoxamin EDTA Chelation Therapy was designed to be less expensive and less complicated than the traditional method of chelati
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    on therapy that uses an intravenous (IV) drip, and has to be given by trained medical personnel in the setting of an outpatient facility.
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    Although this IV chelation has been given to more than one million people over the past 50 years, the process, however beneficial, is, u
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    nfortunately, not only very time-consuming but also prohibitively expensive for many people.

    Instead of being an intravenous drip, Detox
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    amin EDTA is introduced as a rectal suppository, which dissolves at body temperature and is slowly absorbed from the lower bowel into the
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    bloodstream, releasing a 750 mg dosage of Calcium Disodium EDTA over a period of about 80 minutes.

    Removing such toxic heavy metals as
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    mercury, lead, aluminum, arsenic and copper from the body can reduce the risk of such serious health problems as cancer, heart disease, p
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    sychiatric disturbances, speech and language deficits, cognitive (mental) impairments, hearing and vision abnormalities, motor disorders,
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    gastrointestinal difficulties, liver impairment and symptoms related to the cardiovascular, respiratory, immune and reproductive systems


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.advicepool.org.ua/article/226372/advicepool-How-Does-Detoxamin-EDTA-Chelation-Compare-with-Intravenous-Treatment.html">How Does Detoxamin EDTA Chelation Compare with Intravenous Treatment?</a>

    BB link (for phorums):
    [url=http://www.advicepool.org.ua/article/226372/advicepool-How-Does-Detoxamin-EDTA-Chelation-Compare-with-Intravenous-Treatment.html]How Does Detoxamin EDTA Chelation Compare with Intravenous Treatment?[/url]

    Related Articles:

    Learn About Poker Affiliate Online

    How is Forex Trading Different?

    Understanding Mortgage Servicers

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com